Add to ORKGr t ic le This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licens
Abstract Background Nearly 56% of at-risk carriers are not identified and missed as a result of the ...
Objective. The authors developed a Markov decision model to evaluate the health implications of test...
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in ...
Identifying carriers of pathogenic BRCA1/BRCA2 variants reduces cancer morbidity and mortality throu...
Population-based testing for BRCA1/2 mutations detects the high proportion of carriers not identifie...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
r t ic le This is an Open Access article distributed under the terms of the Creative Commons Attribu...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
PurposeTo evaluate the cost-effectiveness of BRCA testing in women with breast cancer, and cascade t...
Purpose: To evaluate the cost-effectiveness of BRCA testing in women with breast cancer, and casc...
This study was funded by ‘The Eve Appeal’ charity. The funding body (The Eve Appeal charity) had no...
BACKGROUND: Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to fam...
Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to family-history ...
Abstract Background Nearly 56% of at-risk carriers are not identified and missed as a result of the ...
Objective. The authors developed a Markov decision model to evaluate the health implications of test...
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in ...
Identifying carriers of pathogenic BRCA1/BRCA2 variants reduces cancer morbidity and mortality throu...
Population-based testing for BRCA1/2 mutations detects the high proportion of carriers not identifie...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
r t ic le This is an Open Access article distributed under the terms of the Creative Commons Attribu...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
PurposeTo evaluate the cost-effectiveness of BRCA testing in women with breast cancer, and cascade t...
Purpose: To evaluate the cost-effectiveness of BRCA testing in women with breast cancer, and casc...
This study was funded by ‘The Eve Appeal’ charity. The funding body (The Eve Appeal charity) had no...
BACKGROUND: Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to fam...
Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to family-history ...
Abstract Background Nearly 56% of at-risk carriers are not identified and missed as a result of the ...
Objective. The authors developed a Markov decision model to evaluate the health implications of test...
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in ...